Cost-effectiveness of brexpiprazole for the treatment of major depressive disorder in Japan
Journal of Affective Disorders · 2025-11 · 388 · 119532
DOI: 10.1016/j.jad.2025.119532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025-11. Verfasst von Yilong Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Otsuka Pharmaceuticals Co., Ltd., Medical Affairs HEOR/RWE, Japan. Hauptthemen laut MEDLINE: Thiophenes, Major Depressive Disorder, Quinolones, Antidepressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical.
Abstract (Originalsprache)
BACKGROUND: Approximately 50 % of patients with major depressive disorder (MDD) do not respond adequately to selective serotonin reuptake inhibitors (SSRI) and serotonin and norepinephrine reuptake inhibitors (SNRI). These patients are candidates for add-on therapy with brexpiprazole. METHODS: A cost-utility analysis was conducted from the Japanese public healthcare payer perspective to compare brexpiprazole and placebo (no add-on) as an adjunct to SSRI/SNRI in patients with MDD and inadequate response to SSRI/SNRI monotherapy. An additional analysis compared initiation of brexpiprazole after 8 (early add-on) and 14 weeks (late add-on). The model followed a cohort of patients participating in clinical trials of brexpiprazole over a total time horizon of 67 weeks. RESULTS: Early add-on of brexpiprazole was cost-effective at the willingness to pay threshold of 5 million JPY/QALY compared with both no add-on and late add-on. Compared with no add-on, patients in the early add-on group gained 0.037 quality-adjusted life-years (QALYs) at an incremental cost of JPY 155,762, resulting in an incremental cost-effectiveness ratio (ICER) of JPY 4.3 million/QALY. Compared with late add-on, early add-on resulted in an incremental gain of 0.008 QALYs at a total cost of JPY 3663, corresponding to an ICER of JPY 0.46 million/QALY. LIMITATIONS: The modelling horizon was restricted to trial duration, so that long-term benefits of brexpiprazole were not captured. There was also uncertainty around incremental QALY gains for early compared with late add-on. CONCLUSION: Brexpiprazole, especially when initiated early, was a cost-effective adjunctive treatment for patients with MDD and a history of inadequate response to SSRI/SNRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otsuka Pharmaceuticals Co., Ltd., Medical Affairs HEOR/RWE, Japan.
- Department of Neuropsychiatry, Keio University School of Medicine, Center for Stress Research, Keio University, Tokyo, Japan.
- Otsuka Pharmaceuticals Co., Ltd., Medical Affairs HEOR/RWE, Japan; Department of Public Health, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Clever-Access, Krakow, Poland.
- Clever-Access, Krakow, Poland. Electronic address: michal.gorecki@clever-access.com.
Förderung
- Otsuka Pharmaceutical
Zitieren
APA
Zhang, Y., Sado, M., Yamato, K., Pochopien, M., & Gorecki, M. (2025). Cost-effectiveness of brexpiprazole for the treatment of major depressive disorder in Japan. Journal of Affective Disorders, 388, 119532. https://doi.org/10.1016/j.jad.2025.119532
Vancouver
Zhang Y, Sado M, Yamato K, Pochopien M, Gorecki M. Cost-effectiveness of brexpiprazole for the treatment of major depressive disorder in Japan. Journal of Affective Disorders. 2025;388:119532. doi:10.1016/j.jad.2025.119532
BibTeX
@article{Zhang2025,
author = {Zhang, Yilong and Sado, Mitsuhiro and Yamato, Kentaro and Pochopien, Michal and Gorecki, Michal},
title = {Cost-effectiveness of brexpiprazole for the treatment of major depressive disorder in Japan},
journal = {Journal of Affective Disorders},
year = {2025},
volume = {388},
pages = {119532},
doi = {10.1016/j.jad.2025.119532}
}
EUVIMED